Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07203-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Sejal Chopra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Serine Endopeptidases, Gelatinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: PGIMER.
Abstract (Originalsprache)
INTRODUCTION: Cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) in the adrenocortical carcinoma (ACC) microenvironment may be used as potential therapeutic targets. This study investigated the diagnostic potential of four FAPi derivatives i.e. DOTA-FAPi-46 (FAPi46), DOTA.SA.FAPi (SA.FAPi), DATA5m.SA.FAPi (DATA.FAPi) and DATA5m.C4.FAPi (C4.FAPi) and compared with standard-of-care 18F-FDG (FDG) in ACC. METHODS: Thirty histopathological proven cases of localized or metastatic ACC were recruited for both FDG and FAPi PET (number of patients (n) = 5 for SA.FAPi, n = 5 for DATA.FAPi, n = 5 for C4.FAPi and n = 15 for FAPi46). For biodistribution, standardized uptake values (SUV's) were computed by delineating region-of-interest on various body organs. For comparative analysis in disease identification, lesion tracer uptake was quantified using standardized uptake values corrected for lean body mass (SUL), tumor-to-background ratio (TBR), total lesion glycolysis (TLG for FDG) and total lesion FAP expression (TLF for FAPi). RESULTS: In overall analysis, both FAPi and FDG PET exhibited comparable mean SULpeak [FAPi 4.3 (8.0-1.7) vs FDG 3.9 (8.1-2.5), p-0.271], mean SULavg [2.2 (4.3-1.2) vs 2.2 (3.4-1.3), p-0.897] and mean TBR [1.8 (3.2-1.2) vs 1.9 (2.7-1.2), p-0.696]. In volumetric analysis, comparable mean TLF and mean TLG was noted for the cohort [9.3 (53.7-4.5) vs 11.8 (33.0-4.3), p-0.107]. Sub-categorical analysis demonstrated complete concordant findings for both radiotracers in detection of all primary lesions, nodal lesions and distant metastases in lung and peritoneum with discordant findings in liver (22%) and skeletal lesions (33%). For lesion detection, DATA.FAPi and FAPi46 showed 100% concordance with FDG scan findings in metastatic disease. SA.FAPi exhibited 33% discordance by detecting an additional skeletal lesion, while C4.FAPi had 10% discordance, missing one liver lesion identified by FDG. Three 68 Ga-FAP derivatives (SA.FAPi, DATA.FAPi, and C4.FAPi) exhibited similar biodistribution, with uptake in the salivary glands, thyroid, liver, pancreas, muscles, and kidneys, and variable uptake in the lacrimal glands, extra-ocular muscles, oral mucosa, and uterus. In contrast, FAPi46 physiological expression was noted in salivary glands and muscles, with no uptake in other organs. Pancreatic uptake was highest for SA.FAPi (SUVmean 11.8), DATA.FAPi (12.1), and C4.FAPi (10.8), while FAPi46 had the lowest (1.7). Conversely, FAPi46 exhibited the highest muscle uptake (SUVmean 4.3) compared to SA.FAPi (1.7), DATA.FAPi (1.4), and C4.FAPi (1.0). CONCLUSION: All the existing FAP inhibitor molecules were comparable to FDG PET for mapping disease spread and appeared as potential theranostic targets for the management of ACC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
- Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. shuklajaya@gmail.com.
- Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
- Department of Chemistry, Johannes Gutenberg University, Mainz, Germany.
- Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. ramawaliapgimer@gmail.com.
ORCID-Profile: Jaya Shukla
Förderung
- PGIMER
Zitieren
APA
Chopra, S., Shukla, J., Purohit, P., Adhikari, U., Roesch, F., Moon, E. S., Rathore, Y., Rana, N., Bhadada, S. K., Mittal, B. R., & Walia, R. (2025). Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07203-4
Vancouver
Chopra S, Shukla J, Purohit P, Adhikari U, Roesch F, Moon ES, et al. Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07203-4
BibTeX
@article{Chopra2025,
author = {Chopra, Sejal and Shukla, Jaya and Purohit, Priyavrat and Adhikari, Umanath and Roesch, Frank and Moon, Euy Sung and Rathore, Yogesh and Rana, Nivedita and Bhadada, Sanjay Kumar and Mittal, Bhagwant Rai and Walia, Rama},
title = {Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07203-4}
}
EUVIMED